My thesis is that for a development-stage biotech, the second and third pipeline projects are basically irrelevant. If the first one wins they are good; if they first one fails they are going to tank badly.
Personally I think those earlier-stage projects are mostly there so the execs still have a job if their first program tanks. On average, I'd call them value-destroying.
Market Data 
Markets 
AI
